Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Janux Therapeutics Inc today. The company’s shares closed yesterday at $23.31.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stranahan covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Agios Pharma, and Novavax. According to TipRanks, Stranahan has an average return of -6.2% and a 46.61% success rate on recommended stocks.
Janux Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $74.44, implying a 219.35% upside from current levels. In a report released on September 16, Barclays also initiated coverage with a Buy rating on the stock with a $47.00 price target.
Based on Janux Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.86 million. In comparison, last year the company earned a revenue of $8.9 million and had a GAAP net loss of $5.96 million
Read More on JANX:
Disclaimer & DisclosureReport an Issue
- Janux Therapeutics Announces Departure of Chief Strategy Officer
- Janux Therapeutics initiated with an Overweight at Barclays
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Janux Therapeutics initiated with a Buy at Truist
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements
/Microsoft%20sign%20at%20the%20headquarters%20by%20VDB%20Photos%20via%20Shutterstock.jpg)
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)